Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/AnaptysBio, Inc./ 10-K

Annual Report · 10-K

AnaptysBio, Inc.

ANABNASDAQEQUITYCurrent

Annual Report

Filed Mar 3, 2026Accepted Mar 3, 2026, 4:23 PM ESTCIK 1370053Accession 0001193125-26-088290
View company →Permanent SEC source ↗
Share

Company context

Anaptys manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www. AnaptysBio.com or follow us on LinkedIn.

Current securities

ANABNASDAQ · EQUITY · Current

Recent company filings

  1. 10-KT filingSep 21, 2026
  2. Financial Statements and ExhibitsSep 21, 2026
  3. SCHEDULE 13G/A filingAug 14, 2026
  4. Submission of Matters to a Vote of Security HoldersAug 11, 2026
  5. Regulation FD DisclosureJul 30, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗